Please contact our sales team for your Consulting and Customization queries/concerns at [email protected].
The primary factor driving the growth of the human microbiome market is the increasing focus on human microbiome therapy development. As a result, the Human Microbiome Market will reach $1,370 million by 2029 from USD 269 million in 2023, at a CAGR of 31.1 from 2023 to 2029. In addition, the human microbiome as a validated target for developing human microbiome & drug development is also expected to support market growth.
However, a lack of expertise and inadequate research on the human microbiome can restrain this market’s growth. Depending on the product, the human microbiome market is segmented into prebiotics, probiotics, drugs, diagnostic test, and other products. The drugs segment accounted for the most extensive product segment in the human microbiome market. The large share of this segment can be attributed to the increasing number of human microbiome-based drug products in clinical trials and rising funding to develop microbiome-based drugs.
Depending on the application, the human microbiome market is categorized into therapeutics and diagnostics. The diagnostics segment is expected to grow at the highest CAGR during the estimated period. Advances in life science research on many diseases, technological innovation in human genome mapping, the emergence of omics technologies, and the rising emphasis on improving the cost-effectiveness of healthcare and patient outcomes are some of the vital factors driving the segment growth.
North America is predicted to maintain its vanguard during the estimated period in the human microbiome market. Factors like the rising incidence of lifestyle diseases, rising awareness of preventive healthcare, availability of funding for microbiome research, and growing acceptance of probiotics are the crucial factors driving the North American human microbiome market.
Breakdown of primaries
The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:
Prominent players in the human microbiome market include ENTEROME Bioscience (France) and Seres Therapeutics. (US), 4D pharma (UK), OptiBiotix Health (UK), Synlogic (US), International flavours & Fragrances (US), Second Genome (US), Vedanta Biosciences (US), Ferring Pharmaceuticals (Switzerland), Evelo Biosciences (US), ViThera Pharmaceuticals (US), BiomX (Israel), Kaleido (US), YSOPIA Bioscience (France), FlightPath (US), Finch Therapeutics (US), Quantbiome (DBA Thyrve, Inc.) (US), Viome, Inc. (the US), DayTwo (US), BIOHM (US), Atlas Biomed (UK), Bione (India), Luxia Scientific (France), Sun Genomics (US), and Metabiomics (US).
The human microbiome market report provides the knowledge of all the crucial factors with supreme quality, transparent, and wide-ranging market studies. The market segmentation study covers analysis and research based on numerous market and industry segments such as vertical, application, deployment model, geography, and end-user. A reliable market report is a top-notch solution that businesses can adopt to thrive in this swiftly changing marketplace. The human microbiome market report also highlights the competitive landscape that offers details of a competitor. The details included about the competitive landscape are company financials, revenue generated, company overview, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch and application dominance.O
Order a Copy of this Research Report at https://www.reportsnreports.com/purchase.aspx?name=297417
